Literature DB >> 11123040

Glucocorticoid-induced osteoporosis.

P Boulos1, G Ioannidis, J D Adachi.   

Abstract

This article attempts to evaluate the results of several recently published clinical trials of drugs used in the treatment and prevention of glucocorticoid-induced osteoporosis. Despite our lack of understanding regarding the biological mechanisms that lead to glucocorticoid-induced bone loss, effective therapy has been developed. Bisphosphonates have demonstrated significant treatment benefits and should be considered the therapy of choice for both the treatment and prevention of glucocorticoid-induced osteoporosis.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11123040     DOI： 10.1007/s11926-996-0069-4

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN： 1523-3774            Impact factor:   4.592


  43 in total

1.  Corticosteroid effects on proximal femur bone loss.

Authors:  P Sambrook; J Birmingham; S Kempler; P Kelly; S Eberl; N Pocock; M Yeates; J Eisman
Journal:  J Bone Miner Res       Date:  1990-12       Impact factor: 6.741

2.  Generalised bone loss in patients with early rheumatoid arthritis.

Authors:  A K Gough; J Lilley; S Eyre; R L Holder; P Emery
Journal:  Lancet       Date:  1994-07-02       Impact factor: 79.321

3.  The ineffectiveness of cyclical oral clodronate on bone mineral density in glucocorticoid-treated patients with giant-cell arteritis.

Authors:  E Nordborg; C Schaufelberger; R Andersson; I Bosaeus; B A Bengtsson
Journal:  J Intern Med       Date:  1997-11       Impact factor: 8.989

4.  Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group.

Authors:  C Roux; P Oriente; R Laan; R A Hughes; J Ittner; S Goemaere; O Di Munno; J M Pouillès; S Horlait; B Cortet
Journal:  J Clin Endocrinol Metab       Date:  1998-04       Impact factor: 5.958

5.  Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients.

Authors:  S Gonnelli; P Rottoli; C Cepollaro; C Pondrelli; V Cappiello; M Vagliasindi; C Gennari
Journal:  Calcif Tissue Int       Date:  1997-11       Impact factor: 4.333

6.  Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis.

Authors:  J R Tucci; R P Tonino; R D Emkey; C A Peverly; U Kher; A C Santora
Journal:  Am J Med       Date:  1996-11       Impact factor: 4.965

7.  Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

Authors:  U A Liberman; S R Weiss; J Bröll; H W Minne; H Quan; N H Bell; J Rodriguez-Portales; R W Downs; J Dequeker; M Favus
Journal:  N Engl J Med       Date:  1995-11-30       Impact factor: 91.245

8.  Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.

Authors:  K G Saag; R Emkey; T J Schnitzer; J P Brown; F Hawkins; S Goemaere; G Thamsborg; U A Liberman; P D Delmas; M P Malice; M Czachur; A G Daifotis
Journal:  N Engl J Med       Date:  1998-07-30       Impact factor: 91.245

9.  Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis.

Authors:  J P Devogelaer; H Broll; R Correa-Rotter; D C Cumming; C N De Deuxchaisnes; P Geusens; D Hosking; P Jaeger; J M Kaufman; M Leite; J Leon; U Liberman; C J Menkes; P J Meunier; I Reid; J Rodriguez; A Romanowicz; E Seeman; A Vermeulen; L J Hirsch; A Lombardi; K Plezia; A C Santora; A J Yates; W Yuan
Journal:  Bone       Date:  1996-02       Impact factor: 4.398

10.  Glucocorticoid-induced inhibition of osteoblastic bone formation in ewes: a biochemical and histomorphometric study.

Authors:  P Chavassieux; P Pastoureau; M C Chapuy; P D Delmas; P J Meunier
Journal:  Osteoporos Int       Date:  1993-03       Impact factor: 4.507
View more
  3 in total

1.  Green tea polyphenols attenuate deterioration of bone microarchitecture in female rats with systemic chronic inflammation.

Authors:  C-L Shen; J K Yeh; C Samathanam; J J Cao; B J Stoecker; R Y Dagda; M-C Chyu; D M Dunn; J-S Wang
Journal:  Osteoporos Int       Date:  2010-03-20       Impact factor: 4.507

Review 2.  Glucocorticoids and osteocyte autophagy.

Authors:  Wei Yao; Weiwei Dai; Jean X Jiang; Nancy E Lane
Journal:  Bone       Date:  2013-01-26       Impact factor: 4.398

3.  Synergistic effects of green tea polyphenols and alphacalcidol on chronic inflammation-induced bone loss in female rats.

Authors:  C-L Shen; J K Yeh; J J Cao; O L Tatum; R Y Dagda; J-S Wang
Journal:  Osteoporos Int       Date:  2010-01-13       Impact factor: 4.507
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.